5 year clinical outcomes of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent: The ISAR-TEST trial

Lamin A King, Julinda Mehilli, Stefanie Schulz,
Robert A Byrne, Albert Schömig, Adnan Kastrati
and
Intracoronary Stenting and Angiographic Restenosis – Test Equivalence Between Two Drug-Eluting Stents (ISAR-TEST) Trial Investigators

Deutsches Herzzentrum,
Technische Universität,
Munich, Germany

No potential conflicts of interest

Speaker's name: Dr Lamin King

☐ **I do not have any potential conflict of interest**

ISAR-TEST: TRIAL DESIGN

DESIGN:
Prospective, randomized, two-center clinical trial

INCLUSION:
De novo native coronary artery stenosis ≥50% AND symptoms or objective evidence of ischaemia

EXCLUSION:
Left main stem disease
MI within 48 hours
Contraindication to study drugs



ISAR-TEST Primary Outcomes: Equivalence at 9 months





Mehilli et al, Circulation 2006

ISAR-TEST: 5 YEAR DATA

ISAR-TEST: Definite Stent Thrombosis



ISAR-TEST: Cardiac death or MI



ISAR-TEST: TLR



ISAR-TEST: MACE



ISAR-TEST: Conclusion

Low incidence of adverse events between year 1 and year 5 for both stent platforms

Polymer-free sirolimus-eluting stent demonstrates over 5 years

- ☐ **durability of efficacy**
- ☐ **durability of safety**

Comparable to a polymer-based stent platform